{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:56:47Z","timestamp":1792119407119,"version":"4.4.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG 2020 ID 24815"],"award-info":[{"award-number":["IG 2020 ID 24815"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Intrahepatic Cholangiocarcinoma (iCCA) is characterized by a strong stromal reaction playing a role in tumor progression. Thymus cell antigen 1 (\n                      <jats:italic>THY1<\/jats:italic>\n                      ), also called Cluster of Differentiation 90 (CD90), is a key regulator of cell\u2013cell and cell\u2013matrix interaction. In iCCA, CD90 has been reported to be associated with a poor prognosis. In an iCCA PDX model, we recently found that CD90 was downregulated in mice treated with the Notch \u03b3-secretase inhibitor Crenigacestat. The study aims to investigate the role of CD90 in relation to the NOTCH pathway.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      THY1\/CD90 gene and protein expression was evaluated in human iCCA tissues and xenograft models by qRT-PCR, immunohistochemistry, and immunofluorescence. Notch1 inhibition was achieved by siRNA. THY1\/CD90 functions were investigated in xenograft models built with HuCCT1 and KKU-M213 cell lines, engineered to overexpress or knockdown\n                      <jats:italic>THY1<\/jats:italic>\n                      , respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      CD90 co-localized with EPCAM, showing its epithelial origin. In vitro,\n                      <jats:italic>NOTCH1<\/jats:italic>\n                      silencing triggered\n                      <jats:italic>HES1<\/jats:italic>\n                      and\n                      <jats:italic>THY1<\/jats:italic>\n                      down-regulation.\n                      <jats:italic>RBPJ<\/jats:italic>\n                      , a critical transcriptional regulator of NOTCH signaling, exhibited putative binding sites on the\n                      <jats:italic>THY1<\/jats:italic>\n                      promoter and bound to the latter, implying CD90 as a downstream NOTCH pathway effector. In vivo, Crenigacestat suppressed iCCA growth and reduced CD90 expression in the PDX model. In the xenograft model, Crenigacestat inhibited tumor growth of HuCCT1 cells transfected to overexpress CD90 and KKU-M213 cells constitutively expressing high levels of CD90, while not affecting the growth of HuCCT1 control cells and KKU-M213 depleted of CD90. In an iCCA cohort, patients with higher expression levels of\n                      <jats:italic>NOTCH1\/HES1\/THY1<\/jats:italic>\n                      displayed a significantly shorter survival.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>iCCA patients with higher NOTCH1\/HES1\/THY1 expression have the worst prognosis, but they are more likely to benefit from Notch signaling inhibition. These findings represent the scientific rationale for testing NOTCH1 inhibitors in clinical trials, taking the first step toward precision medicine for iCCA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-022-02283-8","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T08:04:45Z","timestamp":1644998685000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["CD90 is regulated by notch1 and hallmarks a more aggressive intrahepatic cholangiocarcinoma phenotype"],"prefix":"10.1186","volume":"41","author":[{"given":"Serena","family":"Mancarella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Serino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Gigante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Ribback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Sanese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Grossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano","family":"Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Armentano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Evert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego F.","family":"Calvisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Giannelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,16]]},"reference":[{"key":"2283_CR1","doi-asserted-by":"crossref","unstructured":"Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol [Internet]. 2020;17:557\u201388. Available from: http:\/\/www.nature.com\/articles\/s41575-020-0310-z","DOI":"10.1038\/s41575-020-0310-z"},{"key":"2283_CR2","doi-asserted-by":"publisher","unstructured":"Cai Z, He C, Zhao C, Lin X. Survival Comparisons of Hepatic Arterial Infusion Chemotherapy With mFOLFOX and Transarterial Chemoembolization in Patients With Unresectable Intrahepatic Cholangiocarcinoma. Front Oncol [Internet]. 2021;11. Available from: https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fonc.2021.611118\/full","DOI":"10.3389\/fonc.2021.611118\/full"},{"key":"2283_CR3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1186\/s12885-021-08247-z","volume":"21","author":"C Tawarungruang","year":"2021","unstructured":"Tawarungruang C, Khuntikeo N, Chamadol N, Laopaiboon V, Thuanman J, Thinkhamrop K, et al. Survival after surgery among patients with cholangiocarcinoma in Northeast Thailand according to anatomical and morphological classification. BMC Cancer. 2021;21:497. https:\/\/doi.org\/10.1186\/s12885-021-08247-z.","journal-title":"BMC Cancer"},{"key":"2283_CR4","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.soc.2019.06.002","volume":"28","author":"R El-Diwany","year":"2019","unstructured":"El-Diwany R, Pawlik TM, Ejaz A. Intrahepatic Cholangiocarcinoma. Surg Oncol Clin N Am. 2019;28:587\u201399. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1055320719300444.","journal-title":"Surg Oncol Clin N Am"},{"key":"2283_CR5","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1096\/fj.05-5460rev","volume":"20","author":"TA Rege","year":"2006","unstructured":"Rege TA, Hagood JS. Thy-1 as a regulator of cell-cell and cell-matrix interactions in axon regeneration, apoptosis adhesion migration cancer and fibrosis. FASEB J. 2006;20:1045\u201354. https:\/\/doi.org\/10.1096\/fj.05-5460rev.","journal-title":"FASEB J"},{"key":"2283_CR6","doi-asserted-by":"publisher","first-page":"4710","DOI":"10.1038\/sj.onc.1208559","volume":"24","author":"A Saalbach","year":"2005","unstructured":"Saalbach A, Wetzel A, Haustein U-F, Sticherling M, Simon JC, Anderegg U. Interaction of human Thy-1 (CD 90) with the integrin \u03b1v\u03b23 (CD51\/CD61): an important mechanism mediating melanoma cell adhesion to activated endothelium. Oncogene. 2005;24:4710\u201320. Available from: http:\/\/www.nature.com\/articles\/1208559.","journal-title":"Oncogene"},{"key":"2283_CR7","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13048-019-0590-5","volume":"12","author":"EV Connor","year":"2019","unstructured":"Connor EV, Saygin C, Braley C, Wiechert AC, Karunanithi S, Crean-Tate K, et al. Thy-1 predicts poor prognosis and is associated with self-renewal in ovarian cancer. J Ovarian Res. 2019;12:112. Available from: https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-019-0590-5.","journal-title":"J Ovarian Res"},{"key":"2283_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.yexmp.2010.05.005","volume":"89","author":"S Lingala","year":"2010","unstructured":"Lingala S, Cui Y-Y, Chen X, Ruebner BH, Qian X-F, Zern MA, et al. Immunohistochemical staining of cancer stem cell markers in hepatocellular carcinoma. Exp Mol Pathol. 2010;89:27\u201335. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014480010000705.","journal-title":"Exp Mol Pathol"},{"key":"2283_CR9","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.acthis.2011.01.001","volume":"113","author":"J-W Lu","year":"2011","unstructured":"Lu J-W, Chang J-G, Yeh K-T, Chen R-M, Tsai JJP, Hu R-M. Overexpression of Thy1\/CD90 in human hepatocellular carcinoma is associated with HBV infection and poor prognosis. Acta Histochem. 2011;113:833\u20138. Available from:https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S006512811100002X.","journal-title":"Acta Histochem"},{"key":"2283_CR10","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/jso.25192","volume":"118","author":"R Yamaoka","year":"2018","unstructured":"Yamaoka R, Ishii T, Kawai T, Yasuchika K, Miyauchi Y, Kojima H, et al. CD90 expression in human intrahepatic cholangiocarcinoma is associated with lymph node metastasis and poor prognosis. J Surg Oncol. 2018;118:664\u201374. https:\/\/doi.org\/10.1002\/jso.25192.","journal-title":"J Surg Oncol"},{"key":"2283_CR11","doi-asserted-by":"crossref","unstructured":"Mancarella S, Serino G, Dituri F, Cigliano A, Ribback S, Wang J, et al. Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA\/DLL4\/MMP13 axis. Cell Death Differ [Internet]. 2020; Available from: http:\/\/www.nature.com\/articles\/s41418-020-0505-4","DOI":"10.1038\/s41418-020-0505-4"},{"key":"2283_CR12","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1242\/dev.029140","volume":"136","author":"Y Zong","year":"2009","unstructured":"Zong Y, Panikkar A, Xu J, Antoniou A, Raynaud P, Lemaigre F, et al. Notch signaling controls liver development by regulating biliary differentiation. Development. 2009;136:1727\u201339. Available from: https:\/\/journals.biologists.com\/dev\/article\/136\/10\/1727\/43711\/Notch-signaling-controls-liver-development-by.","journal-title":"Development"},{"key":"2283_CR13","doi-asserted-by":"publisher","first-page":"12250","DOI":"10.1073\/pnas.1600067113","volume":"113","author":"RV Guest","year":"2016","unstructured":"Guest RV, Boulter L, Dwyer BJ, Kendall TJ, Man T-Y, Minnis-Lyons SE, et al. Notch3 drives development and progression of cholangiocarcinoma. Proc Natl Acad Sci. 2016;113:12250\u20135. https:\/\/doi.org\/10.1073\/pnas.1600067113.","journal-title":"Proc Natl Acad Sci"},{"key":"2283_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/liv.14102","volume":"39","author":"L Fouassier","year":"2019","unstructured":"Fouassier L, Marzioni M, Afonso MB, Dooley S, Gaston K, Giannelli G, et al. Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance. Liver Int. 2019;39:43\u201362. https:\/\/doi.org\/10.1111\/liv.14102.","journal-title":"Liver Int"},{"key":"2283_CR15","doi-asserted-by":"crossref","unstructured":"Che L, Fan B, Pilo MG, Xu Z, Liu Y, Cigliano A, et al. Jagged 1 is a major Notch ligand along cholangiocarcinoma development in mice and humans. Oncogenesis [Internet]. 2016;5:e274\u2013e274. Available from: http:\/\/www.nature.com\/articles\/oncsis201673","DOI":"10.1038\/oncsis.2016.73"},{"key":"2283_CR16","doi-asserted-by":"crossref","unstructured":"Dreos R, Ambrosini G, Cavin P\u00e9rier R, Bucher P. EPD and EPDnew, high-quality promoter resources in the next-generation sequencing era. Nucleic Acids Res [Internet]. 2013;41:D157\u201364. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23193273","DOI":"10.1093\/nar\/gks1233"},{"key":"2283_CR17","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1242\/dev.124.20.4133","volume":"124","author":"H Kato","year":"1997","unstructured":"Kato H, Taniguchi Y, Kurooka H, Minoguchi S, Sakai T, Nomura-Okazaki S, et al. Involvement of RBP-J in biological functions of mouse Notch1 and its derivatives. Development. 1997;124:4133\u201341 https:\/\/journals.biologists.com\/dev\/article\/124\/20\/4133\/39518\/Involvement-of-RBP-J-in-biological-functions-of.","journal-title":"Development"},{"key":"2283_CR18","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1038\/s41388-018-0188-1","volume":"37","author":"J Wang","year":"2018","unstructured":"Wang J, Dong M, Xu Z, Song X, Zhang S, Qiao Y, et al. Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice. Oncogene. 2018;37:3229\u201342 http:\/\/www.nature.com\/articles\/s41388-018-0188-1.","journal-title":"Oncogene"},{"key":"2283_CR19","doi-asserted-by":"crossref","unstructured":"Fan B, Malato Y, Calvisi DF, Naqvi S, Razumilava N, Ribback S, et al. Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest [Internet]. 2012;122:2911\u20135. Available from: http:\/\/www.jci.org\/articles\/view\/63212","DOI":"10.1172\/JCI63212"},{"key":"2283_CR20","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3892\/ol.2021.12451","volume":"21","author":"L Gao","year":"2021","unstructured":"Gao L, Li J, He J, Liang L, He Z, Yue C, et al. CD90 affects the biological behavior and energy metabolism level of gastric cancer cells by targeting the PI3K\/AKT\/HIF-1\u03b1 signaling pathway. Oncol Lett. 2021;21:191. https:\/\/doi.org\/10.3892\/ol.2021.12451.","journal-title":"Oncol Lett"},{"key":"2283_CR21","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1007\/s12072-019-09954-3","volume":"13","author":"KS Ahn","year":"2019","unstructured":"Ahn KS, O\u2019Brien D, Kang YN, Mounajjed T, Kim YH, Kim T-S, et al. Prognostic subclass of intrahepatic cholangiocarcinoma by integrative molecular\u2013clinical analysis and potential targeted approach. Hepatol Int. 2019;13:490\u2013500. https:\/\/doi.org\/10.1007\/s12072-019-09954-3.","journal-title":"Hepatol Int"},{"key":"2283_CR22","doi-asserted-by":"crossref","unstructured":"Wu K, Zou J, Lin C, Jie Z-G. MicroRNA-140-5p inhibits cell proliferation, migration and promotes cell apoptosis in gastric cancer through the negative regulation of THY1-mediated Notch signaling. Biosci Rep [Internet]. 2019;39. Available from: https:\/\/portlandpress.com\/bioscirep\/article\/doi\/10.1042\/BSR20181434\/219283\/MicroRNA1405p-inhibits-cell-proliferation","DOI":"10.1042\/BSR20181434"},{"key":"2283_CR23","doi-asserted-by":"publisher","unstructured":"Lake RJ, Tsai P-F, Choi I, Won K-J, Fan H-Y. RBPJ, the Major Transcriptional Effector of Notch Signaling, Remains Associated with Chromatin throughout Mitosis, Suggesting a Role in Mitotic Bookmarking. Fortini M, editor. PLoS Genet [Internet]. 2014;10:e1004204. Available from: https:\/\/dx.plos.org\/https:\/\/doi.org\/10.1371\/journal.pgen.1004204","DOI":"10.1371\/journal.pgen.1004204"},{"key":"2283_CR24","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.celrep.2018.12.097","volume":"26","author":"Z Yuan","year":"2019","unstructured":"Yuan Z, VanderWielen BD, Giaimo BD, Pan L, Collins CE, Turkiewicz A, et al. Structural and Functional Studies of the RBPJ-SHARP Complex Reveal a Conserved Corepressor Binding Site. Cell Rep. 2019;26:845-854.e6. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211124718320576.","journal-title":"Cell Rep"},{"key":"2283_CR25","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1073\/pnas.1315023111","volume":"111","author":"H Wang","year":"2014","unstructured":"Wang H, Zang C, Taing L, Arnett KL, Wong YJ, Pear WS, et al. NOTCH1-RBPJ complexes drive target gene expression through dynamic interactions with superenhancers. Proc Natl Acad Sci. 2014;111:705\u201310. https:\/\/doi.org\/10.1073\/pnas.1315023111.","journal-title":"Proc Natl Acad Sci"},{"key":"2283_CR26","doi-asserted-by":"publisher","unstructured":"Severson E, Arnett KL, Wang H, Zang C, Taing L, Liu H, et al. Genome-wide identification and characterization of Notch transcription complex\u2013binding sequence-paired sites in leukemia cells. Sci Signal [Internet]. 2017;10:eaag1598. Available from: https:\/\/stke.sciencemag.org\/lookup\/doi\/https:\/\/doi.org\/10.1126\/scisignal.aag1598","DOI":"10.1126\/scisignal.aag1598"},{"key":"2283_CR27","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1080\/15384101.2019.1578144","volume":"18","author":"L Chen","year":"2019","unstructured":"Chen L, Tang R-Z, Ruan J, Zhu X-B, Yang Y. Up-regulation of THY1 attenuates interstitial pulmonary fibrosis and promotes lung fibroblast apoptosis during acute interstitial pneumonia by blockade of the WNT signaling pathway. Cell Cycle. 2019;18:670\u201381. https:\/\/doi.org\/10.1080\/15384101.2019.1578144.","journal-title":"Cell Cycle"},{"key":"2283_CR28","doi-asserted-by":"publisher","unstructured":"Parry P V., Engh JA. CD90 is Identified as a Marker for Cancer Stem Cells in High-Grade Gliomas Using Tissue Microarrays. Neurosurgery [Internet]. 2012;70:N23\u20134. Available from: https:\/\/academic.oup.com\/neurosurgery\/article-lookup\/doi\/https:\/\/doi.org\/10.1227\/01.neu.0000413227.80467.92","DOI":"10.1227\/01.neu.0000413227.80467.92"},{"key":"2283_CR29","doi-asserted-by":"crossref","unstructured":"Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, et al. Significance of CD90+ Cancer Stem Cells in Human Liver Cancer. Cancer Cell [Internet]. 2008;13:153\u201366. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610808000093","DOI":"10.1016\/j.ccr.2008.01.013"},{"key":"2283_CR30","doi-asserted-by":"publisher","first-page":"957","DOI":"10.4251\/wjgo.v12.i9.957","volume":"12","author":"B Rauff","year":"2020","unstructured":"Rauff B, Malik A, Bhatti YA, Chudhary SA, Qadri I, Rafiq S. Notch signalling pathway in development of cholangiocarcinoma. World J Gastrointest Oncol. 2020;12:957\u201374. Available from: https:\/\/www.wjgnet.com\/1948-5204\/full\/v12\/i9\/957.htm.","journal-title":"World J Gastrointest Oncol"},{"key":"2283_CR31","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/hep.27268","volume":"61","author":"F Geisler","year":"2015","unstructured":"Geisler F, Strazzabosco M. Emerging roles of Notch signaling in liver disease. Hepatology. 2015;61:382\u201392. https:\/\/doi.org\/10.1002\/hep.27268.","journal-title":"Hepatology"},{"key":"2283_CR32","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0165-4608(02)00855-5","volume":"143","author":"HR Abeysinghe","year":"2003","unstructured":"Abeysinghe HR, Cao Q, Xu J, Pollock S, Veyberman Y, Guckert NL, et al. THY1 expression is associated with tumor suppression of human ovarian cancer. Cancer Genet Cytogenet. 2003;143:125\u201332. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12781446.","journal-title":"Cancer Genet Cytogenet"},{"key":"2283_CR33","unstructured":"Yang G, Chao K, Li X, Rao H, Deng H, Wu H, et al. [Significance of expression of THY1 protein in epithelial ovarian cancer]. Zhonghua Zhong Liu Za Zhi [Internet]. 2009;31:203\u20137. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19615261"},{"key":"2283_CR34","doi-asserted-by":"publisher","first-page":"42923","DOI":"10.18632\/oncotarget.5976","volume":"6","author":"W-C Chen","year":"2015","unstructured":"Chen W-C, Chang Y-S, Hsu H-P, Yen M-C, Huang H-L, Cho C-Y, et al. Therapeutics targeting CD90-integrin-AMPK-CD133 signal axis in liver cancer. Oncotarget. 2015;6:42923\u201337. https:\/\/doi.org\/10.18632\/oncotarget.5976.","journal-title":"Oncotarget"},{"key":"2283_CR35","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1002\/cyto.a.22220","volume":"81A","author":"ARM Lobba","year":"2012","unstructured":"Lobba ARM, Forni MF, Carreira ACO, Sogayar MC. Differential expression of CD90 and CD14 stem cell markers in malignant breast cancer cell lines. Cytom Part A. 2012;81A:1084\u201391. https:\/\/doi.org\/10.1002\/cyto.a.22220.","journal-title":"Cytom Part A"},{"key":"2283_CR36","doi-asserted-by":"publisher","unstructured":"Zhang K, Che S, Pan C, Su Z, Zheng S, Yang S, et al. The <scp>SHH<\/scp> \/Gli axis regulates <scp>CD<\/scp> 90\u2010mediated liver cancer stem cell function by activating the <scp>IL<\/scp> 6\/ <scp>JAK<\/scp> 2 pathway. J Cell Mol Med [Internet]. 2018;22:3679\u201390. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1111\/jcmm.13651","DOI":"10.1111\/jcmm.13651"},{"key":"2283_CR37","doi-asserted-by":"publisher","first-page":"9525","DOI":"10.18632\/oncotarget.6672","volume":"7","author":"J Luo","year":"2016","unstructured":"Luo J, Wang P, Wang R, Wang J, Liu M, Xiong S, et al. The Notch pathway promotes the cancer stem cell characteristics of CD90+ cells in hepatocellular carcinoma. Oncotarget. 2016;7:9525\u201337. https:\/\/doi.org\/10.18632\/oncotarget.6672.","journal-title":"Oncotarget"},{"key":"2283_CR38","doi-asserted-by":"publisher","unstructured":"Kollert F, Christoph S, Probst C, Budweiser S, Bannert B, Binder M, et al. Soluble CD90 as a potential marker of pulmonary involvement in systemic sclerosis. Arthritis Care Res (Hoboken) [Internet]. 2013;65:281\u20137. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1002\/acr.21799","DOI":"10.1002\/acr.21799"},{"key":"2283_CR39","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s004419900079","volume":"298","author":"A Saalbach","year":"1999","unstructured":"Saalbach A, Wetzig T, Haustein UF, Anderegg U. Detection of human soluble Thy-1 in serum by ELISA. Cell Tissue Res. 1999;298:307\u201315. https:\/\/doi.org\/10.1007\/s004419900079.","journal-title":"Cell Tissue Res"},{"key":"2283_CR40","doi-asserted-by":"publisher","first-page":"12709","DOI":"10.1016\/S0021-9258(18)37811-6","volume":"263","author":"P Almqvist","year":"1988","unstructured":"Almqvist P, Carlsson SR. Characterization of a hydrophilic form of Thy-1 purified from human cerebrospinal fluid. J Biol Chem. 1988;263:12709\u201315. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/2900838.","journal-title":"J Biol Chem"},{"key":"2283_CR41","doi-asserted-by":"crossref","unstructured":"True LD, Zhang H, Ye M, Huang C-Y, Nelson PS, von Haller PD, et al. CD90\/THY1 is overexpressed in prostate cancer-associated fibroblasts and could serve as a cancer biomarker. Mod Pathol [Internet]. 2010;23:1346\u201356. Available from: http:\/\/www.nature.com\/articles\/modpathol2010122","DOI":"10.1038\/modpathol.2010.122"},{"key":"2283_CR42","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21:671\u201384. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470204520301091.","journal-title":"Lancet Oncol"},{"key":"2283_CR43","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jhep.2020.03.007","volume":"73","author":"A Lamarca","year":"2020","unstructured":"Lamarca A, Barriuso J, McNamara MG, Valle JW. Molecular targeted therapies: Ready for \u201cprime time\u201d in biliary tract cancer. J Hepatol. 2020;73:170\u201385. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827820301653.","journal-title":"J Hepatol"},{"key":"2283_CR44","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1055\/s-0043-102581","volume":"55","author":"D Walter","year":"2017","unstructured":"Walter D, Hartmann S, Waidmann O. Update on cholangiocarcinoma: potential impact of genomic studies on clinical management. Z Gastroenterol. 2017;55:575\u201381. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28376540.","journal-title":"Z Gastroenterol"}],"updated-by":[{"DOI":"10.1186\/s13046-023-02661-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000}}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-022-02283-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-022-02283-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-022-02283-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:55:46Z","timestamp":1681779346000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-022-02283-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,16]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2283"],"URL":"https:\/\/doi.org\/10.1186\/s13046-022-02283-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1261041\/v1","asserted-by":"object"}]},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,16]]},"assertion":[{"value":"14 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13046-023-02661-w","URL":"https:\/\/doi.org\/10.1186\/s13046-023-02661-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal experiments were approved by the Ethics Committee (Prot. N. 20\/2017, date of release 10\/06\/2017) and conducted at the Biogem Animal House in Ariano Irpino (Avellino, Italy) following the Guide for the Care and Use of Laboratory Animals.Human iCCA samples were collected at the Medical Universities of Greifswald (Greifswald, Germany) and Regensburg (Regensburg, Germany). Institutional Review Board approval was provided by the local Ethical Committees of the Medical University of Greifswald and Regensburg (approval # BB 67\/10 and 17\u20131015-101, respectively) in compliance with the Helsinki Declaration. Informed consent was obtained from all individuals. Demographic and clinicopathological characteristics of patients are summarized in Supplementary Table\n                      \n                      .","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"65"}}